ArticleJournal of medical biochemistry2025
The serum levels of IL-8, IL-10, and TNF-a, cardiac troponin I, creatine kinase-MB in patients with rheumatic heart disease received dexmedetomidine.
Article in Journal of medical biochemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This study aimed to evaluate the effects of dexmedetomidine (DEX) in patients undergoing valve replacement surgery for rheumatic heart disease (RHD), focusing on its impact on serum levels of inflammatory markers (IL-8, IL-10, TNF-a) and myocardial injury markers (Cardiac Troponin I [cTnI], Creatine Kinase-MB [CK-MB]). Methods: A total of 140 patients undergoing cardiopulmonary bypass (CPB) valve replacement surgery at West China Hospital, Sichuan University, between January 2022 and December 2024 were randomly assigned to two groups: the observation group (DEX) and the control group (normal saline). Key perioperative parameters were analysed, including anaesthetic dosage, myocardial injury markers, immune function (CD4+, CD8+, and CD4+/CD8+ ratio), inflammatory factors, and adverse reactions. Results: The observation group required significantly lower anaesthetic dosages than the control group. Additionally, the observation group exhibited higher heart rate (HR) at T5 and higher mean arterial pressure (MAP) at T2, T3, and T5 (P< 0.05). Myocardial injury markers (cTnI and CK-MB) were significantly lower in the observation group (P< 0.05). While preoperative cellular immune function (CD4+, CD8+, and CD4+/CD8+) was similar between both groups, postoperative measurements showed significantly higher CD4+ and CD4+/CD8+ ratios, and lower CD8+ in the observation group (P < 0.05). Regarding inflammatory markers, IL-8 and TNF-a levels were significantly lower, while IL-10 was higher in the observation group postoperatively (P < 0 .0 5). There were no significant differences in adverse reactions between the two groups (P > 0 .0 5). Conclusions: Dexmedetomidine (DEX) reduces anaesthetic usage, supports hemodynamic stability, mitigates myocardial injury, and lowers postoperative inflammatory responses in patients undergoing RHD valve replacement surgery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.